Francisco Partners Iv, L.P. Sells 1,296,177 Shares of GoodRx (NASDAQ:GDRX) Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $3.50, for a total value of $4,536,619.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Tuesday, August 25th, Francisco Partners Iv, L.P. sold 127,273 shares of GoodRx stock. The stock was sold at an average price of $3.44, for a total value of $437,819.12.
• On Monday, August 24th, Francisco Partners Iv, L.P. sold 143,594 shares of GoodRx stock. The stock was sold at an average price of $3.46, for a total value of $496,835.24.
• On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total value of $961,509.50.
• On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The shares were sold at an average price of $3.52, for a total value of $1,574,351.68.
• On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The shares were sold at an average price of $3.53, for a total value of $1,666,071.75.

GoodRx Stock Down 3.8%

GDRX stock opened at $3.51 on Friday. GoodRx Holdings, Inc. has a twelve month low of $1.77 and a twelve month high of $5.81. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $1.20 billion, a P/E ratio of 87.77, a PEG ratio of 1.82 and a beta of 1.60. The firm has a 50 day simple moving average of $3.19 and a 200-day simple moving average of $2.67.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.08. The business had revenue of $200.41 million during the quarter, compared to analyst estimates of $193.23 million. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The business’s revenue was down 1.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.09 earnings per share. On average, equities research analysts predict that GoodRx Holdings, Inc. will post 0.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Barclays increased their price target on shares of GoodRx from $3.00 to $4.00 and gave the stock an “underweight” rating in a research report on Thursday, August 20th. TD Cowen upped their price objective on GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. UBS Group upped their price objective on GoodRx from $2.50 to $3.75 and gave the company a “neutral” rating in a research note on Thursday, August 13th. Wall Street Zen upgraded GoodRx from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Finally, Citigroup boosted their price target on GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $4.23.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GDRX. AQR Capital Management LLC grew its stake in GoodRx by 124.4% during the 1st quarter. AQR Capital Management LLC now owns 282,320 shares of the company’s stock worth $1,245,000 after buying an additional 156,482 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in GoodRx by 7.5% in the first quarter. Goldman Sachs Group Inc. now owns 783,378 shares of the company’s stock valued at $3,455,000 after buying an additional 54,783 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of GoodRx during the first quarter valued at $370,000. Creative Planning acquired a new position in shares of GoodRx during the second quarter valued at $93,000. Finally, Cetera Investment Advisers bought a new position in shares of GoodRx during the second quarter worth about $50,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.